APCR
0.004
300%
IMC
0.039
-40%
MEU
0.12
71.4%
JNS
0.058
-38.9%
IFG
0.017
70%
TMB
0.049
-34.7%
VRC
0.01
66.7%
MIO
0.02
-33.3%
ALV
0.085
63.5%
PET
0.014
-30%
CTN
0.003
50%
CRS
0.091
-27.2%
IMM
0.375
47.1%
DTM
0.035
-27.1%
PER
0.01
42.9%
BAP
1.76
-25.1%
AUA
0.04
37.9%
NES
0.006
-25%
STV
0.011
37.5%
A11
0.155
-24.4%
ELS
2.67
35.5%
WNX
0.125
-24.2%
AGY
0.095
33.8%
AM5
0.007
-22.2%
ALY
0.012
33.3%
KLV
0.007
-22.2%
CHM
0.004
33.3%
NFL
0.11
-21.4%
RHY
0.105
32.9%
MNB
0.023
-20.7%
AR9
0.13
32.7%
CKA
0.054
-20.6%
ASL
2.43
31.4%
HVY
0.5
-20%
X2M
0.013
30%
TYX
0.004
-20%
LRM
0.031
29.2%
LKY
0.205
-19.6%
SPD
1.565
28.8%
SUM
0.033
-19.5%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Neuren Pharmaceuticals Limited (ASX:NEU): Reports top-line results from its Phase 2 clinical trial

Neuren Pharmaceuticals Limited (ASX:NEU) has reported top-line results from its Phase 2 clinical trial of NNZ-2591 in children with Angelman syndrome.

🩺 Clinician and caregiver global efficacy measures specifically designed for Angelman syndrome showed a level of improvement
💊 NNZ-2591 was safe and well tolerated as an oral liquid dose, with no serious adverse events
⚕️Results further strengthen confidence in potential of NNZ-2591 for multiple neurodevelopmental disorders

ASX announcement ⚡ https://announcements.asx.com.au/asxpdf/20240809/pdf/066gd3hmzlyp3z.pdf Jon Pilcher